Rapamycin (Sirolimus) Pipeline and Next-Gen mTOR Inhibitors

HealthRX.com

Rapamycin is not FDA-approved for aging or longevity

Print or save as PDF

Key numbers

  • 48-weekDuration of the PEARL trial in healthy adults given placebo or compounded rapamycin 5 mg or 10 mg weeklySource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 20%Better influenza vaccine antibody response with everolimus in elderly volunteers, at well-tolerated dosesSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 10.9 monthsMedian overall survival with temsirolimus 25 mg weekly in untreated metastatic renal-cell carcinoma, versus 7.3 months with interferon alfaSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 43% to 46%Hypercholesterolemia rate in renal transplant patients taking Rapamune with daily transplant dosing, versus 23% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Sirolimus

At a glance

  • Approved uses / Renal transplant rejection prophylaxis (age 13 and older) and LAM [5]
  • Longevity status / Off-label; no approved aging, longevity or healthspan indication [5]
  • PEARL trial / 48 weeks, weekly 5 mg or 10 mg; primary endpoint unchanged, p=0.942 [1]
  • Other mTOR data / Everolimus (vaccine response), temsirolimus (renal-cell cancer) [3][4]

Approved Uses of Rapamune (Sirolimus)

Rapamune tablets and oral solution are approved for prophylaxis of organ rejection in patients aged 13 and older receiving renal transplants, and for treatment of LAM [5]. There is no approved indication for aging, longevity or healthspan [5]. Using sirolimus for aging is off-label [5]. Compounded rapamycin is not FDA-approved, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [6]; PEARL used compounded rapamycin [1].

What the Human Longevity Trials Show

PEARL, published in Aging in 2025, was a 48-week double-blind, placebo-controlled trial in healthy, normative-aging adults who received placebo, 5 mg or 10 mg compounded rapamycin once weekly [1]. The primary outcome, visceral adiposity by DXA, did not change significantly (p=0.942). Adverse and serious adverse events were similar across groups, and blood biomarkers stayed within normal ranges. Lean tissue mass and self-reported pain improved in women taking 10 mg; emotional well-being and general health improved in those taking 5 mg. The authors concluded that low-dose intermittent rapamycin was relatively safe over 48 weeks and that efficacy was not established [1].

An earlier pilot randomized 25 generally healthy adults aged 70 to 95 to 1 mg rapamycin daily or placebo; 11 rapamycin and 14 placebo participants completed at least 8 weeks [2]. The rapamycin group had statistically significant decreases in hemoglobin, hematocrit, red cell count, RDW, MCV and MCH [2].

What people on Reddit report

Reader accounts from rapamycin forum threads about using it for longevity and about side effects, including people who stopped taking it and people who report mouth ulcers.

aHumanRaisedByHumans · immortalists

I am betting that caloric restriction and any mimetics for it like rapamycin will do nothing for us to lengthen maximum human lifespan.

A commenter doubts that rapamycin will extend human maximum lifespan and expects other approaches to be needed.

Read the source discussion

IndividualAgile731 · immortalists

Bryan Johnson said it did the opposite, made him age faster. It does negate the effects of exercise and weight training.

A commenter reports that a well-known longevity user felt it sped up aging and that it blunted the benefits of exercise.

Read the source discussion

Last_Legs1 · immortalists

Bryan Johnson was on it and jumped off it after some side effects basically wasn't worth it for him

A commenter says a well-known longevity user stopped rapamycin because side effects were not worth it.

Read the source discussion

Diane98661 · Rapamycin

I'd be very cautious before starting rapamycin. In one episode (don't remember which) Peter said he needs to cycle off rapamycin every 5or 6 weeks, due to mouth sores. That scared me off from considering it.

A commenter says mouth sores led them to avoid starting rapamycin after hearing that a user had to cycle off it.

Read the source discussion

MaleficentRemote2586 · Rapamycin

Mouth ulcers are a very common issue for people who take rapamycin

A commenter says mouth ulcers are common among people taking rapamycin.

Read the source discussion

Mouse Data and Other mTOR Inhibitors

Harrison and colleagues reported in Nature in 2009 that rapamycin fed to mice from 600 days of age extended lifespan, with a 14% increase in females and 9% in males based on age at 90% mortality [7]. A later study at a threefold higher dose found median lifespan increases of 23% in males to 26% in females [8]. These are mouse findings.

Everolimus (RAD001), a different mTOR inhibitor, produced about a 20% better antibody response to influenza vaccine in elderly volunteers at doses that were relatively well tolerated [3]. In a 626-patient trial in previously untreated, poor-prognosis metastatic renal-cell carcinoma, intravenous temsirolimus 25 mg weekly gave a median overall survival of 10.9 months versus 7.3 months with interferon alfa (hazard ratio for death 0.73) [4]. Deleting S6K1, a component of mTOR signaling, increased lifespan in mice [9].

What the Rapamune Label Warns About

The boxed warning covers increased susceptibility to infection and possible lymphoma and other malignancies, particularly of the skin, and states that Rapamune is not recommended in liver or lung transplant patients [5]. In renal transplant trials, hypercholesterolemia occurred in 43% to 46% and hypertriglyceridemia in 45% to 57% of Rapamune-treated patients, versus 23% for each in placebo controls [5]. Those rates come from daily transplant dosing, not weekly longevity dosing. The label says to avoid strong CYP3A4/P-gp inducers such as rifampin and strong inhibitors such as ketoconazole and clarithromycin, and that grapefruit juice must not be taken with Rapamune [5].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. Which of these is an approved use of Rapamune according to the article?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Questions worth asking

Choose the questions you want to keep

Frequently asked questions

Is rapamycin FDA-approved for anti-aging?
No. The approved uses are renal transplant rejection prophylaxis in patients aged 13 and older and treatment of LAM. Longevity use is off-label, and compounded rapamycin is not FDA-approved. [5][6]
What did the PEARL trial find?
PEARL was a 48-week double-blind, placebo-controlled trial of weekly 5 mg or 10 mg compounded rapamycin in healthy adults. Visceral adiposity, the primary outcome, did not change significantly (p=0.942). Adverse events were similar across groups, and the authors said efficacy was not established. [1]
What other mTOR inhibitors have human trial data?
Everolimus improved influenza vaccine antibody response by about 20% in elderly volunteers. Temsirolimus 25 mg weekly gave a median overall survival of 10.9 months versus 7.3 months with interferon alfa in a trial of metastatic renal-cell carcinoma. [3][4]

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Can you give me some examples of mTOR inhibitors?

Three mTOR inhibitors are described: rapamycin (sirolimus), everolimus (RAD001) and temsirolimus. Rapamune is the approved form of sirolimus, used for transplant rejection and LAM. Everolimus was tested for influenza vaccine response in elderly volunteers, and temsirolimus, given intravenously at 25 mg weekly, was tested in metastatic renal-cell carcinoma.

What is the difference between rapamycin and everolimus?

No direct comparison of the two is given. Everolimus (RAD001) is a different mTOR inhibitor with human data on influenza vaccine response in elderly volunteers. Rapamycin's approved uses are renal transplant rejection prophylaxis in patients aged 13 and older and treatment of LAM.

References

Show all 11 referencesHide references
  1. Moel M, Harinath G, Lee V, Nyquist A, Morgan SL, Isman A, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025;17(4):908-936.
  2. Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp Gerontol. 2018;105:53-69.
  3. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
  4. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-81.
  5. U.S. National Library of Medicine, DailyMed. Rapamune sirolimus tablets and oral solution (Pfizer) prescribing information. Rapamune sirolimus tablets and oral solution (Pfizer) label
  6. Compounding and the FDA: Questions and Answers | FDA.
  7. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-5.
  8. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13(3):468-77.
  9. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009;326(5949):140-4.
  10. Reddit participants. Is it time to start Rapamycin? (r/immortalists). Accessed 2026-11-11.
  11. Reddit participants. How New Human Data Are Clarifying Rapamycin Dosing for Aging (r/Rapamycin). Accessed 2026-11-11.
Evidence overview for Rapamycin (Sirolimus) Pipeline and Next-Gen mTOR Inhibitors